GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide, and the community runs it mostly for skin rejuvenation and anti-aging, with smaller followings for hair growth and wound healing. People most commonly dose around 2 milligrams daily across a wide reported range, while clinician protocols sit lower, roughly 200 micrograms to 1.5 milligrams daily by injection in four-to-eight-week cycles. Isolated reports of injection-site reactions, flushing, and sleep changes occasionally surface, but none are a consistent theme. The honest caveat: there is no FDA-approved use, and the off-label evidence base is thinner than the discourse suggests, mostly exploratory work without posted results.

Half-life~12 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice2.01.74.02.95.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Human evidence for GHK-Cu is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 2 additional indications (Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds); Treatment studies).

Depthhow much
1 registered trial
1 recruiting / active
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 1 single-trial long-tail
Qualityhow rigorous
No completed trials
Breadth and depth30 rows captured
Human
direct clinical signal
6
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

1
Ameano PeptidesCode lukeclifford
USA
1000 mg
$35.00
$0.04/mg
2
Hong Kong
1000 mg×10
$50.00
$0.05/mg
3
--
1000 mg×10
$56.00
$0.06/mg
4
--
1000 mg
$55.00
$0.06/mg
5
US
1000 mg×10
$58.00
$0.06/mg
6
CN
1000 mg×10
$99.00
$0.1/mg

price offers can be sorted by column

Some links are affiliate links. This never affects our rankings or inclusion.

1-6 of 392

GHK-CU dosing & protocol

How GHK-CU is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 5
Typical dose
100 mg
typical
0
20 mg
40 mg
60 mg
80 mg
100 mg
across 1 dosed source · darker = more agree
Frequency
daily

The trials used a fixed 100 mg dose each day, and no cyclical pattern was reported overall across the five studies.

5 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Starting dose
200 µg200 µg – 1.5 mg
start
0
20 mg
40 mg
60 mg
80 mg
100 mg
distribution of 6 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
topical

Clinician reports of topical GHK‑CU use show doses ranging from 200 mcg to 1.5 mg, applied once or twice daily, with no established cycling protocol.

2 sources
Anecdotal
Community-reported real-world use · n = 131
Typical dose
2 mg100 µg – 50 mg
typical
0
20 mg
40 mg
60 mg
80 mg
100 mg
distribution of 157 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mostly daily
Route
topical
Cycle
varies · e.g. 5 days on / 2 days off (3 reports)

Most users who specified a schedule take GHK‑CU daily, typically around 2 mg, while a smaller group dose every other day or weekly; many did not state a schedule, and a few report cycling such as 5 days on/2 days off.

131 sources